May 23, 2017

RE: PALB2 Study to Evaluate Patient Outcomes

Dear Colleague,

We are writing to tell you about a new study to evaluate outcomes of individuals with pathogenic or likely pathogenic PALB2 mutations. This study is a partnership between our groups based in Toronto, Canada and Nashville, Tennessee. The underlying premise of our efforts stems from our recent observations which suggest that PALB2 carriers are more likely to develop aggressive breast cancers, possibly with poorer outcomes.1 The goals of the proposed study are to collect information needed to refine treatment among women with a PALB2 mutation and breast cancer, in order to improve their outcomes.

We request your help in making this study known to your patient(s). Furthermore, if your patient agrees to be contacted by our study team, please provide current contact information for your patient by email (ICARE@InheritedCancer.net) or phone (615-875-2444). You may also direct them to our website, http://inheritedcancer.net/palb2-study/, where they may learn more about this study or directly enroll online through ICARE. Additionally, patient referrals to these efforts can contribute to your program’s National Accreditation Program for Breast Centers (NAPBC) and Commission on Cancer (CoC) accreditation research requirements.

Additional educational opportunities available to you include: 1) attendance at our web-based monthly genetic case conferences and 2) access to bi-annual newsletters focused on inherited cancer predisposition (additional information available at: http://inheritedcancer.net). If these may be of interest to you, please let us know and we are happy to provide you with additional details.

For more information, you or your patients may contact us by phone (615-875-2444) or email (ICARE@InheritedCancer.net).

We thank you for your consideration in collaborating on this study.

Sincerely,

Tuya Pal, MD, FACMG
Clinical Geneticist
Vanderbilt-Ingram Cancer Center

Kelly Metcalfe, RN, PhD
Faculty of Nursing
University of Toronto

Steven Narod, MD, FRCPC, FRSC
Chair of Breast Cancer Research
Women’s College Hospital